The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology.

IF 0.7 4区 医学 Q4 IMMUNOLOGY
Lymphology Pub Date : 2020-06-02 DOI:10.2458/lymph.4649
Consensus Document
{"title":"The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology.","authors":"Consensus Document","doi":"10.2458/lymph.4649","DOIUrl":null,"url":null,"abstract":"This International Society of Lymphology (ISL) Consensus Document is the latest revision of the 1995 Document for the evaluation and management of peripheral lymphedema (1). It is based upon modifications: [A] suggested and published following the 1997 XVI International Congress of Lymphology (ICL) in Madrid, Spain (2), discussed at the 1999 XVII ICL in Chennai, India (3), and considered confirmed at the 2000 (ISL) Executive Committee meeting in Hinterzarten, Germany (4); [B] derived from integration of discussions and written comments obtained during and following the 2001 XVIII ICL in Genoa, Italy as modified at the 2003 ISL Executive Committee meeting in Cordoba, Argentina (5); [C] suggested from comments, criticisms, and rebuttals as published in the December 2004 issue of Lymphology (6); [D] discussed in both the 2005 XX ICL in Salvador, Brazil and the 2007 XXI ICL in Shanghai, China and modified at the 2008 Executive Committee meeting in Naples, Italy (7,8); [E] modified from discussions and written comments from the 2009 XXII ICL in Sydney, Australia, the 2011 XXIII ICL in Malmö, Sweden, the 2012 Executive Committee Meetings (9); [F] discussions at the 2013 XXIV ICL in Rome, Italy, and the 2015 XXV ICL in San Francisco, USA, as well as multiple written comments and feedback from Executive Committee and other ISL members during the 2016 drafting (10); informal discussions at the XXVI ICL in Barcelona, Spain; and [G] discussions at a dedicated, focused Post-Congress session at the XXVII ICL in Iguazú, Argentina (2019) followed by additional written comments from the Executive Committee and others. The document attempts to amalgamate the broad spectrum of protocols and practices advocated worldwide for the diagnosis and treatment of peripheral lymphedema into a coordinated proclamation representing a \"Consensus\" of the international community based on various levels of evidence. The document is not meant to override individual clinical considerations for complex patients nor to stifle progress. It is also not meant to be a legal formulation from which variations define medical malpractice. The Society understands that in some clinics the method of treatment derives from national standards while in others access to medical equipment, technical expertise, and supplies is limited; therefore, the suggested treatments might be impractical. Adaptability and inclusiveness does come at the price that members can rightly be critical of what they see as vagueness or imprecision in definitions, qualifiers in the choice of words (e.g., the use of \"may... perhaps... unclear\", etc.) and mentions (albeit without endorsement) of treatment options supported by limited hard data. Most members are frustrated by the reality that NO treatment method has really undergone a satisfactory meta-analysis (let alone rigorous, randomized, stratified, long-term, controlled study). With this understanding, the absence of definitive answers and optimally conducted clinical trials, and with emerging technologies and new approaches and discoveries on the horizon, some degree of uncertainty, ambiguity, and flexibility along with dissatisfaction with current lymphedema evaluation and management is appropriate and to be expected. We continue to struggle to keep the document concise while balancing the need for depth and details. With these considerations in mind, we believe that this 2020 version presents a Consensus that embraces the entire ISL membership, rises above national standards, identifies and stimulates promising areas for future research, and represents the best judgment of the ISL membership on how to approach patients with peripheral lymphedema in the light of currently available evidence. Therefore, the document has been and should continue to be challenged and debated in the pages of Lymphology (e.g., as Letters to the Editor) and ideally will remain a continued focal point for robust discussion at local, national and international conferences in lymphology and related disciplines. We further anticipate as experience evolves and new ideas and technologies emerge that this \"living document\" will undergo further periodic revision and refinement as the practice and conceptual foundations of medicine and specifically lymphology change and advance.","PeriodicalId":51122,"journal":{"name":"Lymphology","volume":"53 1 1","pages":"3-19"},"PeriodicalIF":0.7000,"publicationDate":"2020-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"382","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lymphology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2458/lymph.4649","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 382

Abstract

This International Society of Lymphology (ISL) Consensus Document is the latest revision of the 1995 Document for the evaluation and management of peripheral lymphedema (1). It is based upon modifications: [A] suggested and published following the 1997 XVI International Congress of Lymphology (ICL) in Madrid, Spain (2), discussed at the 1999 XVII ICL in Chennai, India (3), and considered confirmed at the 2000 (ISL) Executive Committee meeting in Hinterzarten, Germany (4); [B] derived from integration of discussions and written comments obtained during and following the 2001 XVIII ICL in Genoa, Italy as modified at the 2003 ISL Executive Committee meeting in Cordoba, Argentina (5); [C] suggested from comments, criticisms, and rebuttals as published in the December 2004 issue of Lymphology (6); [D] discussed in both the 2005 XX ICL in Salvador, Brazil and the 2007 XXI ICL in Shanghai, China and modified at the 2008 Executive Committee meeting in Naples, Italy (7,8); [E] modified from discussions and written comments from the 2009 XXII ICL in Sydney, Australia, the 2011 XXIII ICL in Malmö, Sweden, the 2012 Executive Committee Meetings (9); [F] discussions at the 2013 XXIV ICL in Rome, Italy, and the 2015 XXV ICL in San Francisco, USA, as well as multiple written comments and feedback from Executive Committee and other ISL members during the 2016 drafting (10); informal discussions at the XXVI ICL in Barcelona, Spain; and [G] discussions at a dedicated, focused Post-Congress session at the XXVII ICL in Iguazú, Argentina (2019) followed by additional written comments from the Executive Committee and others. The document attempts to amalgamate the broad spectrum of protocols and practices advocated worldwide for the diagnosis and treatment of peripheral lymphedema into a coordinated proclamation representing a "Consensus" of the international community based on various levels of evidence. The document is not meant to override individual clinical considerations for complex patients nor to stifle progress. It is also not meant to be a legal formulation from which variations define medical malpractice. The Society understands that in some clinics the method of treatment derives from national standards while in others access to medical equipment, technical expertise, and supplies is limited; therefore, the suggested treatments might be impractical. Adaptability and inclusiveness does come at the price that members can rightly be critical of what they see as vagueness or imprecision in definitions, qualifiers in the choice of words (e.g., the use of "may... perhaps... unclear", etc.) and mentions (albeit without endorsement) of treatment options supported by limited hard data. Most members are frustrated by the reality that NO treatment method has really undergone a satisfactory meta-analysis (let alone rigorous, randomized, stratified, long-term, controlled study). With this understanding, the absence of definitive answers and optimally conducted clinical trials, and with emerging technologies and new approaches and discoveries on the horizon, some degree of uncertainty, ambiguity, and flexibility along with dissatisfaction with current lymphedema evaluation and management is appropriate and to be expected. We continue to struggle to keep the document concise while balancing the need for depth and details. With these considerations in mind, we believe that this 2020 version presents a Consensus that embraces the entire ISL membership, rises above national standards, identifies and stimulates promising areas for future research, and represents the best judgment of the ISL membership on how to approach patients with peripheral lymphedema in the light of currently available evidence. Therefore, the document has been and should continue to be challenged and debated in the pages of Lymphology (e.g., as Letters to the Editor) and ideally will remain a continued focal point for robust discussion at local, national and international conferences in lymphology and related disciplines. We further anticipate as experience evolves and new ideas and technologies emerge that this "living document" will undergo further periodic revision and refinement as the practice and conceptual foundations of medicine and specifically lymphology change and advance.
外周淋巴水肿的诊断和治疗:2020年国际淋巴学会共识文件。
这份国际淋巴学会(ISL)共识文件是1995年外周淋巴水肿评估和管理文件的最新修订(1)。它是基于修改:[A]在1997年西班牙马德里第十六届国际淋巴学大会(ICL)之后提出并发表的(2),在1999年印度钦奈第十七届国际淋巴学会上讨论的(3),并在2000年德国Hinterzarten执行委员会会议上审议确认(4);[B] 源自2001年意大利热那亚第十八届ICL期间和之后获得的讨论和书面评论,经2003年阿根廷科尔多瓦ISL执行委员会会议修订(5);[C] 从2004年12月出版的《淋巴学》(6)上发表的评论、批评和反驳中提出;[D] 在2005年巴西萨尔瓦多第二十届ICL和2007年中国上海第二十一届ICL中进行了讨论,并在2008年意大利那不勒斯执行委员会会议上进行了修改(7,8);[E] 修改自2009年在澳大利亚悉尼举行的第二十二届ICL、2011年在瑞典马尔默举行的第二十三届ICL和2012年执行委员会会议的讨论和书面意见(9);[F] 2013年在意大利罗马举行的第二十四届ICL和2015年在美国旧金山举行的第二十五届ICL的讨论,以及执行委员会和其他ISL成员在2016年起草期间的多份书面意见和反馈(10);在西班牙巴塞罗那举行的第二十六届ICL的非正式讨论;以及[G]在阿根廷伊瓜苏举行的第二十七届ICL大会后专门、重点突出的会议上进行的讨论(2019年),随后执行委员会和其他机构发表了额外的书面意见。该文件试图将世界各地倡导的外周淋巴水肿诊断和治疗的广泛协议和实践合并为一份协调一致的公告,代表国际社会基于各种证据的“共识”。该文件并不是为了凌驾于复杂患者的个别临床考虑之上,也不是为了扼杀进展。它也不意味着是一个法律公式,从中可以定义医疗事故。协会了解到,在一些诊所,治疗方法源自国家标准,而在另一些诊所,获得医疗设备、技术专长和用品的机会有限;因此,建议的治疗方法可能不切实际。适应性和包容性的代价是,成员们可以正确地批评他们所认为的定义的模糊或不精确性、措辞的限定词(例如,使用“可能……也许……不清楚”等)以及提及(尽管没有得到认可)有限硬数据支持的治疗方案。大多数成员对NO治疗方法确实经过了令人满意的荟萃分析(更不用说严格的、随机的、分层的、长期的、对照的研究)感到沮丧。有了这一认识,在缺乏明确答案和最佳临床试验的情况下,随着新兴技术、新方法和新发现的出现,一定程度的不确定性、模糊性和灵活性,以及对当前淋巴水肿评估和管理的不满,是合适的,也是可以预料的。我们继续努力保持文件的简洁性,同时平衡对深度和细节的需求。考虑到这些考虑,我们认为,2020年的版本提出了一个共识,涵盖了整个ISL成员,超过了国家标准,确定并刺激了未来研究的有希望的领域,并代表了ISL成员根据目前可用的证据对如何治疗外周淋巴水肿患者的最佳判断。因此,该文件已经并应该继续在《淋巴学》杂志上受到质疑和辩论(例如,作为给编辑的信),理想情况下,它将继续成为地方、国家和国际淋巴学及相关学科会议上强有力讨论的焦点。我们进一步预计,随着经验的发展和新思想和技术的出现,随着医学,特别是淋巴学的实践和概念基础的变化和进步,这份“活文件”将经历进一步的定期修订和完善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lymphology
Lymphology 医学-免疫学
CiteScore
5.20
自引率
8.00%
发文量
29
审稿时长
3 months
期刊介绍: The Journal contains original articles, special features (see below), and information regarding the International Society of Lymphology. It seeks original papers dealing with clinical and basic studies of the lymphatic system and its disorders including related fields. Articles are accepted for external review and publication on the condition that they are contributed to Lymphology only and that no substantial part has been or will be published elsewhere.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信